

Annette J Vangsted

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3416187/publications.pdf>

Version: 2024-02-01

72
papers

1,081
citations

393982

19
h-index

500791

28
g-index

74
all docs

74
docs citations

74
times ranked

1744
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome data from >10,000 multiple myeloma patients in the Danish and Swedish national registries. <i>European Journal of Haematology</i> , 2022, 108, 99-108.	1.1	9
2	Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group. <i>European Journal of Haematology</i> , 2022, 108, 34-44.	1.1	10
3	A polygenic risk score for multiple myeloma risk prediction. <i>European Journal of Human Genetics</i> , 2022, 30, 474-479.	1.4	5
4	The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	3
5	Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry. <i>British Journal of Haematology</i> , 2021, 193, 119-124.	1.2	12
6	Common gene variants within 3â€²-untranslated regions as modulators of multiple myeloma risk and survival. <i>International Journal of Cancer</i> , 2021, 148, 1887-1894.	2.3	3
7	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. <i>International Journal of Cancer</i> , 2021, 149, 327-336.	2.3	3
8	Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , 2021, 11, 74.	2.8	10
9	Germline variants at SOHLH2 influence multiple myeloma risk. <i>Blood Cancer Journal</i> , 2021, 11, 76.	2.8	6
10	Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio. <i>Blood Cancer Journal</i> , 2021, 11, 70.	2.8	2
11	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	1.7	22
12	Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). <i>Journal of Clinical Oncology</i> , 2021, 39, 3602-3612.	0.8	44
13	Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients. <i>Hematological Oncology</i> , 2021, 39, 521-528.	0.8	1
14	The real-world outcomes of multiple myeloma patients treated with daratumumab. <i>PLoS ONE</i> , 2021, 16, e0258487.	1.1	11
15	The Clinical Course and Life Expectancy of Patients with Multiple Myeloma Who Discontinue Their First Daratumumab-Containing Line of Therapy. <i>Blood</i> , 2021, 138, 3779-3779.	0.6	2
16	Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone. <i>Blood</i> , 2021, 138, 1633-1633.	0.6	1
17	Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 817-817.	0.6	4
18	Clinically-suspected cast nephropathy: A retrospective, national, real-world study. <i>American Journal of Hematology</i> , 2020, 95, 1352-1360.	2.0	9

#	ARTICLE	IF	CITATIONS
19	Human P2X7 Receptor Causes Cycle Arrest in RPMI-8226 Myeloma Cells to Alter the Interaction with Osteoblasts and Osteoclasts. <i>Cells</i> , 2020, 9, 2341.	1.8	9
20	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	3.3	109
21	Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 47-48.	0.6	11
22	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. <i>Leukemia</i> , 2019, 33, 2324-2330.	3.3	33
23	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1803-1811.	0.6	11
24	Clarithromycin added to bortezomib+cyclophosphamide+dexamethasone impairs health-related quality of life in multiple myeloma patients. <i>European Journal of Haematology</i> , 2019, 102, 70-78.	1.1	8
25	The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. <i>Leukemia</i> , 2019, 33, 546-549.	3.3	26
26	A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group. <i>Blood</i> , 2019, 134, 601-601.	0.6	5
27	First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 925-925.	0.6	8
28	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. <i>Blood</i> , 2019, 134, 693-693.	0.6	18
29	Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry. <i>Blood</i> , 2019, 134, 1849-1849.	0.6	2
30	Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study. <i>Blood</i> , 2019, 134, 5553-5553.	0.6	0
31	Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014. <i>Leukemia</i> , 2018, 32, 2054-2057.	3.3	5
32	Lenalidomide versus lenalidomide+dexamethasone prolonged treatment after second-line lenalidomide+dexamethasone induction in multiple myeloma. <i>Cancer Medicine</i> , 2018, 7, 2256-2268.	1.3	1
33	Drug response prediction in high-risk multiple myeloma. <i>Gene</i> , 2018, 644, 80-86.	1.0	14
34	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. <i>British Journal of Haematology</i> , 2018, 183, 375-384.	1.2	11
35	A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma. <i>Experimental Hematology and Oncology</i> , 2018, 7, 18.	2.0	9
36	Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry. <i>American Journal of Hematology</i> , 2017, 92, E611-E614.	2.0	13

#	ARTICLE	IF	CITATIONS
37	The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. <i>Cancer Medicine</i> , 2017, 6, 1807-1816.	1.3	39
38	Identification of miRSNPs associated with the risk of multiple myeloma. <i>International Journal of Cancer</i> , 2017, 140, 526-534.	2.3	8
39	Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. <i>PLoS ONE</i> , 2017, 12, e0188988.	1.1	36
40	A common genetic variant in 19q13.3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3. <i>British Journal of Haematology</i> , 2016, 174, 991-993.	1.2	6
41	Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. <i>European Journal of Haematology</i> , 2016, 97, 303-309.	1.1	54
42	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMENSE consortium and meta-analysis. <i>Oncotarget</i> , 2016, 7, 59029-59048.	0.8	16
43	Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Multiple Myeloma Database. <i>American Journal of Hematology</i> , 2015, 90, E73-4.	2.0	44
44	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. <i>Nature Communications</i> , 2015, 6, 7539.	5.8	38
45	GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis. <i>Supportive Care in Cancer</i> , 2015, 23, 841-849.	1.0	21
46	Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival. <i>European Journal of Haematology</i> , 2015, 94, 60-66.	1.1	8
47	Synergy of two human endogenous retroviruses in multiple myeloma. <i>Leukemia Research</i> , 2015, 39, 1125-1128.	0.4	6
48	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMENSE consortium. <i>Endocrine-Related Cancer</i> , 2015, 22, 545-559.	1.6	11
49	Continued improvement in overall survival in elderly multiple myeloma patients after 2008; a population based study from the Danish Multiple Myeloma Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e189.	0.2	3
50	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. <i>International Journal of Cancer</i> , 2015, 136, E351-8.	2.3	30
51	Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma. <i>European Journal of Haematology</i> , 2014, 93, 172-174.	1.1	7
52	Genetic Variants and Multiple Myeloma Risk: IMMENSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 670-674.	1.1	13
53	Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma. <i>Blood</i> , 2014, 124, 2001-2003.	0.6	17
54	The International Multiple Myeloma Research (IMMENSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis. <i>Blood</i> , 2014, 124, 3421-3421.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. <i>British Journal of Haematology</i> , 2012, 158, 805-809.	1.2	19
56	Vascular endothelial growth factor (<i>VEGF</i>) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. <i>International Journal of Cancer</i> , 2012, 131, E636-42.	2.3	21
57	A functional polymorphism in the promoter region of the <i>IL</i>1<i>B</i> gene is associated with risk of multiple myeloma. <i>British Journal of Haematology</i> , 2012, 158, 515-518.	1.2	22
58	The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP. <i>Annals of Hematology</i> , 2011, 90, 675-684.	0.8	10
59	Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib. <i>Annals of Hematology</i> , 2011, 90, 1173-1181.	0.8	23
60	No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. <i>BMC Cancer</i> , 2010, 10, 404.	1.1	22
61	Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004*. <i>European Journal of Haematology</i> , 2010, 85, 209-216.	1.1	14
62	A polymorphism in NFKB1 is associated with improved effect of interferon- γ maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. <i>Haematologica</i> , 2009, 94, 1274-1281.	1.7	25
63	Strain- and age-dependent natural and activated in vitro cytotoxicity in athymic nude mice. <i>Apmsis</i> , 1994, 102, 481-488.	0.9	10
64	Serological tumor markers for small cell lung cancer and their therapeutic implications. <i>Apmsis</i> , 1994, 102, 561-580.	0.9	4
65	1351-1357.	1.6	6
66	Monoclonal Antibodies for Diagnosis and Potential Therapy of Small Cell Lung Cancer- γ The Ganglioside Antigen Fucosyl-Gm1. <i>Acta Oncologica</i> , 1993, 32, 845-851.	0.8	11
67	Serum immunoassay of a small cell lung cancer associated ganglioside: development of a sensitive scintillation proximity assay. <i>Glycoconjugate Journal</i> , 1992, 9, 331-335.	1.4	8
68	Production of Gastrin-Releasing Peptide-(18-27) and a StaWe Fragment of Its Precursor in Small Cell Lung Carcinoma Cells*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 1586-1593.	1.8	17
69	Oxytocin and vasopressin binding sites in human and bovine ovaries. <i>American Journal of Obstetrics and Gynecology</i> , 1990, 163, 1961-1967.	0.7	43
70	Gastrin releasing peptide (GRP) is present in a GRP(1-27) form in anterior pituitary cells of the guinea pig. <i>Peptides</i> , 1989, 10, 815-818.	1.2	13
71	Oxytocin and vasopressin release by vasoactive intestinal polypeptide (VIP) in normal women. <i>Journal of Obstetrics and Gynaecology</i> , 1988, 9, 83-86.	0.4	2
72	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	1.1	2